Navigation Links
Study Sheds Light on Medication Treatment Options for Bipolar,Disorder

BETHESDA, Md., March 29, 2007--For depressed people with bipolar disorder who are taking a mood stabilizer, adding an antidepressant medication is no more effective than a placebo (sugar pill), according to results published online on March 28, 2007 in the New England Journal of Medicine. The results are part of the large-scale, multi-site Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), a $26.8 million clinical trial funded by the National Institutes of Healths National Institute of Mental Health (NIMH).

Bipolar disorder (http://www.nimh.nih.gov/healthinformation/bipolarmenu.cfm), a sometimes debilitating illness marked by severe mood swings between depression and mania, is usually treated with mood stabilizers such as lithium, valproate, carbamazepine or other medications that reduce mania. However, depression is more common than mania in bipolar disorder, and depressive episodes tend to last longer than episodes of mania. Antidepressant medications are often used in addition to a mood stabilizer for treating bipolar depression, but they are thought to confer a serious risk of a switch from a depressive episode to a manic episode.

Finding the right treatment balance for people with bipolar disorder is a constant challenge; STEP-BD aims to identify the best treatment options. Treating depression in people with bipolar disorder is notoriously difficult, said NIMH Director Thomas R. Insel. STEP-BD sought to determine if adding an antidepressant to a mood stabilizer is effective and safe in treating depressive episodes. The results suggest that antidepressants are safe but not more effective than placebo as assessed in a large number of people with bipolar disorder.

Lead author Gary Sachs, M.D., of Massachusetts General Hospital and colleagues studied 366 participants at 22 sites a
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/19/2008)...ewswire-FirstCall/ --,Pharmaceutical company Pharm... the Phase 3 clinical trial evaluating the long te...tasis has concluded with no serious,adverse events...atment., A total of 123 subjects started treatmen...ects completed the full 12 months of the trial. Of...
(Date:8/19/2008)...- Particle Sciences Inc. has,expanded its Combinat...d,pilot production capabilities with the installat...ing line. The core of the pilot line,comprising a...20T injection,molder, enables the production of hi...ition gives Particle Sciences the ability to go fr...
(Date:8/19/2008)...used to identify molecular,signature of motor neur...-USNewswire/ -- ALS Therapy,Development Institute ...LS,biomarker effort using blood samples collected ...ps. These ongoing projects are part of the,Institu...ression of genes,and proteins, at the onset of, an...
(Date:8/19/2008)...ll/ -- Vical Incorporated,(Nasdaq: VICL ) today a...ska,Institute, a leading European medical universi...se Control (SMI), a governmental expert agency, to...iojector(R) 2000,needle-free injection system (Bio...multivalent preventive DNA vaccine against HIV., ...
Breaking Medicine Technology:12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3Particle Sciences Expands Its Combination Product Capabilities 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 2Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 3Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 4Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control 5Many States Still Fall Short in Emergency Preparedness 3A Report 8484 1Many States Still Fall Short in Emergency Preparedness 3A Report 8484 2Many States Still Fall Short in Emergency Preparedness 3A Report 8484 3Many States Still Fall Short in Emergency Preparedness 3A Report 8484 4Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 1NightHawk Radiology Holdings Inc to Speak at Annual JPMorgan Healthcare Conference on January 10 2008 8481 2SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 1SecureWorks Designated as a Qualified Security Assessor for PCI Audits 8478 2
...ce shortly, CARMIEL, Israel, April 18, 2007 /PRNew.... today announced that it has received,written not...ation,(FDA) that it may initiate a Phase III clini... candidate, prGCD, a proprietary plant,cell expres...GCD),for the treatment of Gaucher Disease, a lyso...
... out of ten patients taking,once-daily Lialda rema...TON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- ...nsion study (303),presented at the British Society...tland in March 2007 showed Shire plc,s,Lialda(mesa...atients. Today, secondary endpoints of study 303 w...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
... of Missouri birth statistics by researchers at Wa...s appearing// in the February issue of the America... African-American women are three times more likel...rematurely than Caucasian women. In addition, th...
..., a clinical assistant professor in Indiana Univer...ience//, has offered some tips to help parents of ...enage children. Teenage is the most difficult pha...and romance form an integral part of this mind-bog...
...ancer-fighting film that could be applied directly... can be made into any size and shape, is capable o... site as it dissolves over several weeks. This eff...bypass administering conventional chemotherapy tre...
...succumbed to the flu, in British Columbia//. The...ly peaks in the months of December and January. Th...ters, say experts. According to Dr. Theresa Tam o...gency of Canada, in an average year, about 4,000 C...
Other Medicine News:Health News:African-American Mothers More Likely to Deliver Prematurely 2Health News:A Better Way to Deliver Cancer Drugs 2Health News:Flu Strikes Late - Child Succumbs 2
...e (GH) is a monomeric protein produced and stored ...H is released from the pituitary into the bloodstr...trol of hypothalamic somatostatin (SS) and GH-rele...of GH release appears to be regulated by somatosta...
...he most potent glucocorticoid produced by the huma...d with high affinity to corticosteroid-binding glo...lbumin. Cortisol acts on specific intracellular re...ms, including immune function, glucose counter-reg...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
Medicine Products: